Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS establishes links with the University of Ghent
2007-11-15

The University of the Free State (UFS) recently formalised its co-operation ties with the University of Ghent in Belgium. The two universities signed a memorandum of understanding during the Accenta Trade Fair, an annual event that incorporates activities such as business seminars, cultural events and exhibitions.

The signing of the memorandum of understanding took place via a live video conference linking the two institutions of higher learning.

“It was a wonderful moment because, after signing the memorandum of understanding on the Main Campus in Bloemfontein, the Rector and Vice-Chancellor, Prof. Frederick Fourie, actually showed us his signature on the screen while we were in Ghent”, said Prof. Koos Bekker of the Department of Public Management at the UFS, who was part of the delegation from the Free State.

The delegation consisted of the Premier, Ms Beatrice Marshoff, and several MECs and senior officials from the Free State provincial government, as well as the mayor, councillors and senior officials of the Mangaung Local Municipality. Several staff members of the UFS were also part of the delegation.

According to Prof. Bekker, the two universities will co-operate in various areas in terms of the memorandum of understanding.

“In the short term the collaboration will be focused on bio-fuels, public management and the digital divide, while discussions in other areas such as health services and organised crime are also under way,” he said.

As part of the memorandum of understanding, the following collaborative efforts are also envisaged:

Mr Lyndon du Plessis, a lecturer in the Department of Public Management, will be enrolled for a Ph.D. at both universities as from September 2008.

A research project involving both universities, the Mangaung Local Municipality and the City of Ghent, will be undertaken.
An investigation will be conducted by both universities regarding the possibility of writing a book on performance management in the public sector (negotiations with the publisher in this regard are under way).

An exchange programme involving students and staff from both universities will be established.

Academics from the UFS delivered papers during one of the forums that formed part of the Accenta Trade Fair programme in Ghent. Prof. Koos Bekker and Mr Lyndon du Plessis from the Department of Public Management delivered papers on strategic planning in practice on the first day of the event, which was devoted to scientific seminars. On the second day Prof. Lucius Botes, Director of the Centre for Development Support at the UFS, delivered a paper on economic development issues, and on the third day Prof. Gustav Visser, Associate Professor in the Department of Geography at the UFS, delivered a paper on tourism.

Papers on bridging the digital divide were presented during the video conference by academics in both Bloemfontein and Ghent.

As guests of honour at the Accenta Trade Fair, the Free State delegation was allocated the main exhibition floor space, covering 1 092 m². The Main Exhibition Hall covers a total surface area of 40 000 m². The Accenta Trade Fair attracts an average of 100 000 visitors annually. The UFS also participated as an exhibitor at the Trade Fair.

This visit was a follow-up of the previous visit, during which the Free State delegation was hosted by the City of Ghent and the provincial government of East Flanders for planning purposes from 14 to 24 April 2007.

Media Release
Issued by: Mangaliso Radebe
Assistant Director: Media Liaison
Tel: 051 401 2828
Cell: 078 460 3320
E-mail: radebemt.stg@ufs.ac.za  
14 November 2007
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept